GlassScriptPhysician profile
Katherine Linder
NPI 1417358367
$2,013.54
in general payments reported to CMS, 2019-2025
26 companies · $943 in 2025
The $943 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.93 · 2022: $144 · 2023: $320 · 2024: $593 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $255.78 | 2022-2025 | |
| Taiho Oncology, INC. | $194.14 | 2024-2025 | |
| Blueprint Medicines Corporation | $189.38 | 2023-2025 | Ayvakit |
| Celgene Corporation | $146.13 | 2022-2025 | Reblozyl, Sprycel |
| Takeda Pharmaceuticals U.S.A., INC. | $135.21 | 2024-2025 | Iclusig |
| Alexion Pharmaceuticals, INC. | $133.82 | 2022-2025 | Ultomiris |
| Geron Corporation | $128.21 | 2024-2025 | Rytelo |
| Pharmaessentia USA Corporation | $92.31 | 2022-2025 | Besremi |
| Daiichi Sankyo INC. | $81.93 | 2023-2025 | Vanflyta, Injectafer |
| Incyte Corporation | $72.73 | 2023-2024 | Jakafi |
| Cti Biopharma Corp. | $72.44 | 2023 | Vonjo |
| Sobi, INC | $71.20 | 2024-2025 | |
| Autolus INC | $70.19 | 2025 | |
| Genzyme Corporation | $50.90 | 2025 | |
| Abbvie INC. | $48.00 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.01 | 2024-2025 | Xospata |
| Glaxosmithkline, LLC. | $39.03 | 2024-2025 | Ojjaara |
| Azurity Pharmaceuticals, INC. | $33.69 | 2025 | Danziten |
| Pharmacyclics LLC, An Abbvie Company | $27.63 | 2022-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $26.84 | 2021-2023 | |
| Rigel Pharmaceuticals, INC. | $21.97 | 2024 | Rezlidhia, Tavalisse |
| Servier Pharmaceuticals LLC | $18.16 | 2025 | |
| Agios Pharmaceuticals, INC. | $17.95 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $16.42 | 2025 | Brukinsa |
| Bard Peripheral Vascular, INC. | $14.90 | 2024 | Trek |
| Adaptive Biotechnologies Corporation | $14.57 | 2024 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Linder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.